Trial of anticancer immunotherapy with immobilized pokeweed mitogen: Immunotherapy by extracorporeal circulation
- 1 March 1990
- journal article
- research article
- Published by Springer Nature in Cancer Immunology, Immunotherapy
- Vol. 32 (2) , 125-130
- https://doi.org/10.1007/bf01754209
Abstract
For the purpose of activating the immune system in the living body, we made use of pokeweed mitogen (PWM). PWM, a type of lectin, has the potential to induce anticancer cells. In order to utilize this potential and apply it to cancer therapy by hemoperfusion with PWM, the lectin is immobilized on the surface of synthetic polymer beads and these beads are packed into a minicolumn. Human peripheral lymphocytes were activated by circulatory contact stimulation through the PWM column for 1 h. After circulatory contact stimulation through the colum, lymphocytes were collected and used as effector cells. Cytotoxicity tests were measured by51Cr-release assay using K-562 cells and Daudi cells for targets. This material could enhance natural killer activity and induce cytotoxicity against natural-killer-resistant Daudi cells. Lymphocytes activated by the PWM column were injected intraregionally into nude mice bearing MKN-1 tumor, and suppression of tumor growth was recognized. Anticancer activities by direct hemoperfusion treatment with a PWM minicolumn were examined in Vx2-tumor-bearing rabbits. A single treatment using the PWM column was performed 6 days after tumor inoculation. Suppression of the tumor growth was observable for 25 days. PWM minicolumns are a likely anticancer material, acting as immunomodulators.Keywords
This publication has 23 references indexed in Scilit:
- A Progress Report on the Treatment of 157 Patients with Advanced Cancer Using Lymphokine-Activated Killer Cells and Interleukin-2 or High-Dose Interleukin-2 AloneNew England Journal of Medicine, 1987
- Observations on the Systemic Administration of Autologous Lymphokine-Activated Killer Cells and Recombinant Interleukin-2 to Patients with Metastatic CancerNew England Journal of Medicine, 1985
- Recombinant interleukin 2 stimulates in vivo proliferation of adoptively transferred lymphokine-activated killer (LAK) cells.The Journal of Immunology, 1985
- Systemic administration of recombinant interleukin 2 stimulates in vivo lymphoid cell proliferation in tissues.The Journal of Immunology, 1985
- SUCCESSFUL IMMUNOTHERAPY OF MURINE EXPERIMENTAL HEPATIC METASTASES WITH LYMPHOKINE-ACTIVATED KILLER CELLS AND RECOMBINANT INTERLEUKIN-21985
- [Plasmapheresis in the patients with malignant tumor].1984
- Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes.The Journal of Experimental Medicine, 1982
- Plasmapheresis in Patients with Advanced Malignant Disease: A Pilot StudyOncology, 1982
- Preliminary Observations of the Effects on Breast Adenocarcinoma of Plasma Perfused over Immobilized Protein ANew England Journal of Medicine, 1981
- PLASMAPHERESIS AND IMMUNOSTIMULATIONThe Lancet, 1976